[{"id":"8c229a43-88ef-4aa6-9cca-dad9d1af3b1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03457142","created_at":"2021-01-18T17:02:40.865Z","updated_at":"2025-02-25T14:38:10.967Z","phase":"Phase 2","brief_title":"Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy","source_id_and_acronym":"NCT03457142","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IL6 • CD28 • CD86","pipe":" | ","alterations":" CD28 expression • IL6 expression","tags":["IL6 • CD28 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD28 expression • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib) • Orencia (abatacept)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/11/2018","start_date":" 09/11/2018","primary_txt":" Primary completion: 11/21/2022","primary_completion_date":" 11/21/2022","study_txt":" Completion: 01/11/2025","study_completion_date":" 01/11/2025","last_update_posted":"2024-05-16"},{"id":"95a652b1-308b-4dec-885c-a10583b02377","acronym":"","url":"https://clinicaltrials.gov/study/NCT01743131","created_at":"2021-01-18T07:37:32.437Z","updated_at":"2024-07-02T16:35:49.415Z","phase":"Phase 2","brief_title":"Abatacept as GVHD Prophylaxis Phase 2","source_id_and_acronym":"NCT01743131","lead_sponsor":"Boston Children's Hospital","biomarkers":" ABL1 • BCR • HLA-DRB1 • CD4","pipe":" | ","alterations":" Chr del(5q)","tags":["ABL1 • BCR • HLA-DRB1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orencia (abatacept)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2023-04-27"},{"id":"591f8526-ce03-4da2-985b-c4d42f183ed9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04000698","created_at":"2021-01-18T19:39:51.048Z","updated_at":"2024-07-02T16:36:38.415Z","phase":"Phase 3","brief_title":"Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias","source_id_and_acronym":"NCT04000698","lead_sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","biomarkers":" BCL2 • CXCR4 • CD38","pipe":" | ","alterations":" CD38 expression • BCL2 expression","tags":["BCL2 • CXCR4 • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • Actemra IV (tocilizumab) • Grafapex (treosulfan) • Orencia (abatacept)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/15/2019","start_date":" 10/15/2019","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-11-20"}]